Research Analysts Set Expectations for Bicycle Therapeutics plc's FY2022 Earnings (NASDAQ:BCYC)

Bicycle Therapeutics plc (NASDAQ:BCYC – Get Rating) – Stock analysts at SVB Leerink decreased their FY2022 EPS estimates for shares of Bicycle Therapeutics in a report released on Tuesday, March 1st. SVB Leerink analyst J. Chang now anticipates that the company will earn ($2.88) per share for the year, down from their prior forecast of […]

Related Keywords

New Jersey ,United States ,Thomson Reuter ,Pierre Legault ,Morgan Stanley ,Bicycle Therapeutics Plc ,Geode Capital Management ,Securities Exchange Commission ,Shilanski Associates Inc ,Zacks Investment Research ,Highmark Wealth Management ,Jersey Common Pension Fund ,Nasdaq ,Needham Company ,Bicycle Therapeutics Company Profile Get Rating ,Bicycle Therapeutics ,Get Rating ,Investment Research ,Capital Management ,Director Pierre Legault ,Exchange Commission ,Therapeutics Company Profile ,Therapeutics Plc ,Nasdaq Bcyc ,Bcyc ,Medical ,Earnings Estimates ,Svb Leerink Llc ,